Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study

Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. Material and methods    A representative sample of the European part o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kardiologiia 2021-03, Vol.61 (4), p.4-14
Hauptverfasser: Polyakov, D S, Fomin, I V, Belenkov, Yu N, Mareev, V Yu, Ageev, F T, Artemjeva, E G, Badin, Yu V, Bakulina, E V, Vinogradova, N G, Galyavich, A S, Ionova, T S, Kamalov, G M, Kechedzhieva, S G, Koziolova, N A, Malenkova, V Yu, Malchikova, S V, Mareev, Yu V, Smirnova, E A, Tarlovskaya, E I, Shcherbinina, E V, Yakushin, S S
Format: Artikel
Sprache:eng ; rus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 14
container_issue 4
container_start_page 4
container_title Kardiologiia
container_volume 61
creator Polyakov, D S
Fomin, I V
Belenkov, Yu N
Mareev, V Yu
Ageev, F T
Artemjeva, E G
Badin, Yu V
Bakulina, E V
Vinogradova, N G
Galyavich, A S
Ionova, T S
Kamalov, G M
Kechedzhieva, S G
Koziolova, N A
Malenkova, V Yu
Malchikova, S V
Mareev, Yu V
Smirnova, E A
Tarlovskaya, E I
Shcherbinina, E V
Yakushin, S S
description Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. Material and methods    A representative sample of the European part of the Russian Federation followed up for 2002 through 2017 (n=19 276); a representative sample of the population of the Nizhny Novgorod region examined in 1998 (n=1922).Results    During the observation period since 2002, the incidence of major CHF symptoms (tachycardia, edema, shortness of breath, weakness) tended to decrease while the prevalence of cardiovascular diseases has statistically significantly increased. During the period from 1998 through 2017, the prevalence of I-IV functional class (FC) CHF increased from 6.1 % to 8.2 % whereas III-IV FC CHF increased from 1.8 % to 3.1 %. The main causes for the development of CHF remained arterial hypertension and ischemic heart disease; the role of myocardial infarction and diabetes mellitus as causes for CHF was noted. For the analyzed period, the number of treatment components and the coverage of basic therapy for patients with CHF increased, which probably accounts for a slower increase in the disease prevalence by 2007-2017. The prognosis of patients was unfavorable: in I-II FC CHF, the median survival was 8.4 (95 % CI: 7.8-9.1) years and in III-IV FC CHF, the median survival was 3.8 (95 % CI: 3.4-4.2) years.
doi_str_mv 10.18087/cardio.2021.4.n1628
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2528436967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528436967</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-e48bb066b0b6ba3f80ff604876c98fab2c3e9e6fbe500079074a2a8c3309b5833</originalsourceid><addsrcrecordid>eNo9kFFr2zAUhcXYWELWf1CGHvvi9FqSZXkvZYSkLRQywvosJPlqNjhWJtkLgf34uUnWpwuH850LHyG3OSxzBaq8dybWbVgyYPlSLPtcMvWBzJnIWVZICR_JHICxrAIBM3KTUmsBZFFyURSfyYzzqlIC-Jz8XTUx9K2jDZo4UG_aboxI254ODdLdOJGmpxusMZqhDf03emzMQBuTqGtM_wtrGv5gpAzoaVpINHjqQ9eFYzYeHugO09gN5_Rtb_1ju3rKVk8bmoaxPn0hn7zpEt5c74K8btY_p8bL9vF59f0lc7zgQ4ZCWQtSWrDSGu4VeC9BqFK6SnljmeNYofQWCwAoKyiFYUY5zqGyheJ8Qe4uu4cYfo-YBr1vk8OuMz2GMWlWMCW4rGQ5VcWl6mJIKaLXh9juTTzpHPRZvb6o12_qtdBn9RP29fphtHus36H_ovk_mlGAsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528436967</pqid></control><display><type>article</type><title>Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Polyakov, D S ; Fomin, I V ; Belenkov, Yu N ; Mareev, V Yu ; Ageev, F T ; Artemjeva, E G ; Badin, Yu V ; Bakulina, E V ; Vinogradova, N G ; Galyavich, A S ; Ionova, T S ; Kamalov, G M ; Kechedzhieva, S G ; Koziolova, N A ; Malenkova, V Yu ; Malchikova, S V ; Mareev, Yu V ; Smirnova, E A ; Tarlovskaya, E I ; Shcherbinina, E V ; Yakushin, S S</creator><creatorcontrib>Polyakov, D S ; Fomin, I V ; Belenkov, Yu N ; Mareev, V Yu ; Ageev, F T ; Artemjeva, E G ; Badin, Yu V ; Bakulina, E V ; Vinogradova, N G ; Galyavich, A S ; Ionova, T S ; Kamalov, G M ; Kechedzhieva, S G ; Koziolova, N A ; Malenkova, V Yu ; Malchikova, S V ; Mareev, Yu V ; Smirnova, E A ; Tarlovskaya, E I ; Shcherbinina, E V ; Yakushin, S S</creatorcontrib><description>Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. Material and methods    A representative sample of the European part of the Russian Federation followed up for 2002 through 2017 (n=19 276); a representative sample of the population of the Nizhny Novgorod region examined in 1998 (n=1922).Results    During the observation period since 2002, the incidence of major CHF symptoms (tachycardia, edema, shortness of breath, weakness) tended to decrease while the prevalence of cardiovascular diseases has statistically significantly increased. During the period from 1998 through 2017, the prevalence of I-IV functional class (FC) CHF increased from 6.1 % to 8.2 % whereas III-IV FC CHF increased from 1.8 % to 3.1 %. The main causes for the development of CHF remained arterial hypertension and ischemic heart disease; the role of myocardial infarction and diabetes mellitus as causes for CHF was noted. For the analyzed period, the number of treatment components and the coverage of basic therapy for patients with CHF increased, which probably accounts for a slower increase in the disease prevalence by 2007-2017. The prognosis of patients was unfavorable: in I-II FC CHF, the median survival was 8.4 (95 % CI: 7.8-9.1) years and in III-IV FC CHF, the median survival was 3.8 (95 % CI: 3.4-4.2) years.</description><identifier>ISSN: 0022-9040</identifier><identifier>EISSN: 2412-5660</identifier><identifier>DOI: 10.18087/cardio.2021.4.n1628</identifier><identifier>PMID: 33998403</identifier><language>eng ; rus</language><publisher>Russia (Federation)</publisher><ispartof>Kardiologiia, 2021-03, Vol.61 (4), p.4-14</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-e48bb066b0b6ba3f80ff604876c98fab2c3e9e6fbe500079074a2a8c3309b5833</citedby><cites>FETCH-LOGICAL-c353t-e48bb066b0b6ba3f80ff604876c98fab2c3e9e6fbe500079074a2a8c3309b5833</cites><orcidid>0000-0002-8725-5422 ; 0000-0002-4241-2025 ; 0000-0002-3105-5149 ; 0000-0002-2814-3180 ; 0000-0001-5841-2364 ; 0000-0002-7285-2048 ; 0000-0002-2209-9457 ; 0000-0002-1939-7189 ; 0000-0002-4510-6197 ; 0000-0002-3014-6129 ; 0000-0003-4369-1393 ; 0000-0003-0334-6237 ; 0000-0002-3391-7937 ; 0000-0002-9659-7010 ; 0000-0001-8421-0168 ; 0000-0003-0258-5279 ; 0000-0001-7003-5186</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33998403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polyakov, D S</creatorcontrib><creatorcontrib>Fomin, I V</creatorcontrib><creatorcontrib>Belenkov, Yu N</creatorcontrib><creatorcontrib>Mareev, V Yu</creatorcontrib><creatorcontrib>Ageev, F T</creatorcontrib><creatorcontrib>Artemjeva, E G</creatorcontrib><creatorcontrib>Badin, Yu V</creatorcontrib><creatorcontrib>Bakulina, E V</creatorcontrib><creatorcontrib>Vinogradova, N G</creatorcontrib><creatorcontrib>Galyavich, A S</creatorcontrib><creatorcontrib>Ionova, T S</creatorcontrib><creatorcontrib>Kamalov, G M</creatorcontrib><creatorcontrib>Kechedzhieva, S G</creatorcontrib><creatorcontrib>Koziolova, N A</creatorcontrib><creatorcontrib>Malenkova, V Yu</creatorcontrib><creatorcontrib>Malchikova, S V</creatorcontrib><creatorcontrib>Mareev, Yu V</creatorcontrib><creatorcontrib>Smirnova, E A</creatorcontrib><creatorcontrib>Tarlovskaya, E I</creatorcontrib><creatorcontrib>Shcherbinina, E V</creatorcontrib><creatorcontrib>Yakushin, S S</creatorcontrib><title>Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study</title><title>Kardiologiia</title><addtitle>Kardiologiia</addtitle><description>Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. Material and methods    A representative sample of the European part of the Russian Federation followed up for 2002 through 2017 (n=19 276); a representative sample of the population of the Nizhny Novgorod region examined in 1998 (n=1922).Results    During the observation period since 2002, the incidence of major CHF symptoms (tachycardia, edema, shortness of breath, weakness) tended to decrease while the prevalence of cardiovascular diseases has statistically significantly increased. During the period from 1998 through 2017, the prevalence of I-IV functional class (FC) CHF increased from 6.1 % to 8.2 % whereas III-IV FC CHF increased from 1.8 % to 3.1 %. The main causes for the development of CHF remained arterial hypertension and ischemic heart disease; the role of myocardial infarction and diabetes mellitus as causes for CHF was noted. For the analyzed period, the number of treatment components and the coverage of basic therapy for patients with CHF increased, which probably accounts for a slower increase in the disease prevalence by 2007-2017. The prognosis of patients was unfavorable: in I-II FC CHF, the median survival was 8.4 (95 % CI: 7.8-9.1) years and in III-IV FC CHF, the median survival was 3.8 (95 % CI: 3.4-4.2) years.</description><issn>0022-9040</issn><issn>2412-5660</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kFFr2zAUhcXYWELWf1CGHvvi9FqSZXkvZYSkLRQywvosJPlqNjhWJtkLgf34uUnWpwuH850LHyG3OSxzBaq8dybWbVgyYPlSLPtcMvWBzJnIWVZICR_JHICxrAIBM3KTUmsBZFFyURSfyYzzqlIC-Jz8XTUx9K2jDZo4UG_aboxI254ODdLdOJGmpxusMZqhDf03emzMQBuTqGtM_wtrGv5gpAzoaVpINHjqQ9eFYzYeHugO09gN5_Rtb_1ju3rKVk8bmoaxPn0hn7zpEt5c74K8btY_p8bL9vF59f0lc7zgQ4ZCWQtSWrDSGu4VeC9BqFK6SnljmeNYofQWCwAoKyiFYUY5zqGyheJ8Qe4uu4cYfo-YBr1vk8OuMz2GMWlWMCW4rGQ5VcWl6mJIKaLXh9juTTzpHPRZvb6o12_qtdBn9RP29fphtHus36H_ovk_mlGAsw</recordid><startdate>20210323</startdate><enddate>20210323</enddate><creator>Polyakov, D S</creator><creator>Fomin, I V</creator><creator>Belenkov, Yu N</creator><creator>Mareev, V Yu</creator><creator>Ageev, F T</creator><creator>Artemjeva, E G</creator><creator>Badin, Yu V</creator><creator>Bakulina, E V</creator><creator>Vinogradova, N G</creator><creator>Galyavich, A S</creator><creator>Ionova, T S</creator><creator>Kamalov, G M</creator><creator>Kechedzhieva, S G</creator><creator>Koziolova, N A</creator><creator>Malenkova, V Yu</creator><creator>Malchikova, S V</creator><creator>Mareev, Yu V</creator><creator>Smirnova, E A</creator><creator>Tarlovskaya, E I</creator><creator>Shcherbinina, E V</creator><creator>Yakushin, S S</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8725-5422</orcidid><orcidid>https://orcid.org/0000-0002-4241-2025</orcidid><orcidid>https://orcid.org/0000-0002-3105-5149</orcidid><orcidid>https://orcid.org/0000-0002-2814-3180</orcidid><orcidid>https://orcid.org/0000-0001-5841-2364</orcidid><orcidid>https://orcid.org/0000-0002-7285-2048</orcidid><orcidid>https://orcid.org/0000-0002-2209-9457</orcidid><orcidid>https://orcid.org/0000-0002-1939-7189</orcidid><orcidid>https://orcid.org/0000-0002-4510-6197</orcidid><orcidid>https://orcid.org/0000-0002-3014-6129</orcidid><orcidid>https://orcid.org/0000-0003-4369-1393</orcidid><orcidid>https://orcid.org/0000-0003-0334-6237</orcidid><orcidid>https://orcid.org/0000-0002-3391-7937</orcidid><orcidid>https://orcid.org/0000-0002-9659-7010</orcidid><orcidid>https://orcid.org/0000-0001-8421-0168</orcidid><orcidid>https://orcid.org/0000-0003-0258-5279</orcidid><orcidid>https://orcid.org/0000-0001-7003-5186</orcidid></search><sort><creationdate>20210323</creationdate><title>Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study</title><author>Polyakov, D S ; Fomin, I V ; Belenkov, Yu N ; Mareev, V Yu ; Ageev, F T ; Artemjeva, E G ; Badin, Yu V ; Bakulina, E V ; Vinogradova, N G ; Galyavich, A S ; Ionova, T S ; Kamalov, G M ; Kechedzhieva, S G ; Koziolova, N A ; Malenkova, V Yu ; Malchikova, S V ; Mareev, Yu V ; Smirnova, E A ; Tarlovskaya, E I ; Shcherbinina, E V ; Yakushin, S S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-e48bb066b0b6ba3f80ff604876c98fab2c3e9e6fbe500079074a2a8c3309b5833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; rus</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polyakov, D S</creatorcontrib><creatorcontrib>Fomin, I V</creatorcontrib><creatorcontrib>Belenkov, Yu N</creatorcontrib><creatorcontrib>Mareev, V Yu</creatorcontrib><creatorcontrib>Ageev, F T</creatorcontrib><creatorcontrib>Artemjeva, E G</creatorcontrib><creatorcontrib>Badin, Yu V</creatorcontrib><creatorcontrib>Bakulina, E V</creatorcontrib><creatorcontrib>Vinogradova, N G</creatorcontrib><creatorcontrib>Galyavich, A S</creatorcontrib><creatorcontrib>Ionova, T S</creatorcontrib><creatorcontrib>Kamalov, G M</creatorcontrib><creatorcontrib>Kechedzhieva, S G</creatorcontrib><creatorcontrib>Koziolova, N A</creatorcontrib><creatorcontrib>Malenkova, V Yu</creatorcontrib><creatorcontrib>Malchikova, S V</creatorcontrib><creatorcontrib>Mareev, Yu V</creatorcontrib><creatorcontrib>Smirnova, E A</creatorcontrib><creatorcontrib>Tarlovskaya, E I</creatorcontrib><creatorcontrib>Shcherbinina, E V</creatorcontrib><creatorcontrib>Yakushin, S S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Kardiologiia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polyakov, D S</au><au>Fomin, I V</au><au>Belenkov, Yu N</au><au>Mareev, V Yu</au><au>Ageev, F T</au><au>Artemjeva, E G</au><au>Badin, Yu V</au><au>Bakulina, E V</au><au>Vinogradova, N G</au><au>Galyavich, A S</au><au>Ionova, T S</au><au>Kamalov, G M</au><au>Kechedzhieva, S G</au><au>Koziolova, N A</au><au>Malenkova, V Yu</au><au>Malchikova, S V</au><au>Mareev, Yu V</au><au>Smirnova, E A</au><au>Tarlovskaya, E I</au><au>Shcherbinina, E V</au><au>Yakushin, S S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study</atitle><jtitle>Kardiologiia</jtitle><addtitle>Kardiologiia</addtitle><date>2021-03-23</date><risdate>2021</risdate><volume>61</volume><issue>4</issue><spage>4</spage><epage>14</epage><pages>4-14</pages><issn>0022-9040</issn><eissn>2412-5660</eissn><abstract>Aim    To study the etiology and the dynamics of prevalence and mortality of CHF; to evaluate the treatment coverage of such patients in a representative sample of the European part of the Russian Federation for a 20-year period. Material and methods    A representative sample of the European part of the Russian Federation followed up for 2002 through 2017 (n=19 276); a representative sample of the population of the Nizhny Novgorod region examined in 1998 (n=1922).Results    During the observation period since 2002, the incidence of major CHF symptoms (tachycardia, edema, shortness of breath, weakness) tended to decrease while the prevalence of cardiovascular diseases has statistically significantly increased. During the period from 1998 through 2017, the prevalence of I-IV functional class (FC) CHF increased from 6.1 % to 8.2 % whereas III-IV FC CHF increased from 1.8 % to 3.1 %. The main causes for the development of CHF remained arterial hypertension and ischemic heart disease; the role of myocardial infarction and diabetes mellitus as causes for CHF was noted. For the analyzed period, the number of treatment components and the coverage of basic therapy for patients with CHF increased, which probably accounts for a slower increase in the disease prevalence by 2007-2017. The prognosis of patients was unfavorable: in I-II FC CHF, the median survival was 8.4 (95 % CI: 7.8-9.1) years and in III-IV FC CHF, the median survival was 3.8 (95 % CI: 3.4-4.2) years.</abstract><cop>Russia (Federation)</cop><pmid>33998403</pmid><doi>10.18087/cardio.2021.4.n1628</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8725-5422</orcidid><orcidid>https://orcid.org/0000-0002-4241-2025</orcidid><orcidid>https://orcid.org/0000-0002-3105-5149</orcidid><orcidid>https://orcid.org/0000-0002-2814-3180</orcidid><orcidid>https://orcid.org/0000-0001-5841-2364</orcidid><orcidid>https://orcid.org/0000-0002-7285-2048</orcidid><orcidid>https://orcid.org/0000-0002-2209-9457</orcidid><orcidid>https://orcid.org/0000-0002-1939-7189</orcidid><orcidid>https://orcid.org/0000-0002-4510-6197</orcidid><orcidid>https://orcid.org/0000-0002-3014-6129</orcidid><orcidid>https://orcid.org/0000-0003-4369-1393</orcidid><orcidid>https://orcid.org/0000-0003-0334-6237</orcidid><orcidid>https://orcid.org/0000-0002-3391-7937</orcidid><orcidid>https://orcid.org/0000-0002-9659-7010</orcidid><orcidid>https://orcid.org/0000-0001-8421-0168</orcidid><orcidid>https://orcid.org/0000-0003-0258-5279</orcidid><orcidid>https://orcid.org/0000-0001-7003-5186</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-9040
ispartof Kardiologiia, 2021-03, Vol.61 (4), p.4-14
issn 0022-9040
2412-5660
language eng ; rus
recordid cdi_proquest_miscellaneous_2528436967
source EZB-FREE-00999 freely available EZB journals
title Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T11%3A36%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20heart%20failure%20in%20the%20Russian%20Federation:%20what%20has%20changed%20over%2020%20years%20of%20follow-up?%20Results%20of%20the%20EPOCH-CHF%20study&rft.jtitle=Kardiologiia&rft.au=Polyakov,%20D%20S&rft.date=2021-03-23&rft.volume=61&rft.issue=4&rft.spage=4&rft.epage=14&rft.pages=4-14&rft.issn=0022-9040&rft.eissn=2412-5660&rft_id=info:doi/10.18087/cardio.2021.4.n1628&rft_dat=%3Cproquest_cross%3E2528436967%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528436967&rft_id=info:pmid/33998403&rfr_iscdi=true